Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30068214 | 0.91 | HTR2A (0.54) | HTR2AMEN1KMT2AMPOALDH1A1 | |
| SCHEMBL2593407 | 0.89 | HTR2A (0.56) | HTR2ACHEK1MEN1KMT2AALDH1A1 | |
| SCHEMBL14768412 | 0.88 | HTR2A (0.54) | HTR2AMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL30068222 | 0.79 | HTR2A (0.54) | HTR2AMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL30068289 | 0.78 | HTR2A (0.65) | HTR2AMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL27173101 | 0.78 | HTR2A (0.64) | HTR2AMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL16206580 | 0.78 | ALDH1A1 (0.46) | HTR2AMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL14968913 | 0.78 | HTR2A (0.57) | HTR2AMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL27173123 | 0.78 | HTR2A (0.67) | HTR2AMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL2589935 | 0.76 | CHEK1 (0.54) | HTR2ACHEK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716287-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | disclosed |
| EP-2569290-A2 | PHARMACEUTICAL COMPOUNDS | Sentinel Oncology Limited (GB) | 2013-03-20 | — | — | EP | disclosed |
| US-20130065900-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| WO-2011141716-A2 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065900-A1 | PHARMACEUTICAL COMPOUNDS | CSNK1A1, FRK, CSNK1E | HTR2A 1755/4885CHEK1 105/4885MEN1 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.